Wednesday, June 10, 2026

P0 · Therapeutic area intelligence

Neurology & CNS patent intelligence

Alzheimer's, Parkinson's, epilepsy, and CNS pharmaceutical patent landscape.

Patents
289

Quick answer

289 US pharmaceutical patents in our index match Neurology & CNS title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10052363

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 9993449

    (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

    Northwestern University · Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 9980931

    Use of glycyl glutamine against depression

    Uludag Universitesi Teknoloji Transfer Ofisi Ticaret Ve Sanayi Anonim Suirketi · Granted Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 9957329

    Factor XII inhibitors for the treatment of neurological inflammatory disorders

    Julius-Maximilians-Universitat Wurzburg · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9867830

    Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9868725

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 9856238

    1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

    PGI Drug Discovery LLC · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 9855226

    d-methadone for the treatment of psychiatric symptoms

    Relmada Therapeutics, Inc. · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 2017340593

    MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE

    BIAL - PORTELA & CA S A [PT] · Granted Thu Nov 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 9821023

    Methods for the treatment of central nervous system (CNS) disorders and mood disorders

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. WO 2017194692

    DERIVES DE LA BENZOXAZINE OU DE LA QUINAZOLINE POUR LEUR UTILISATION DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOCODEX [FR] · Granted Thu Nov 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 9814755

    Methods for the treatment of depression and anxiety

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 9796755

    Methods of treating depression and other related diseases

    Northwestern University · Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9789131

    Compounds and methods for treating neurological and cardiovascular conditions

    The Board of Regents of the University of Texas System · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9757366

    Methods for the treatment of parkinson's disease psychosis using pimavanserin

    ACADIA Pharmaceuticals Inc. · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 9758831

    Methods of predicting clinical course and treating multiple sclerosis

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 9758529

    Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders

    PGI Drug Discovery LLC · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 9737533

    1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

    Addex Pharma, S.A. · Granted Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 9732386

    Cell aging as a unique biomarker of major depression

    The Regents of the University of California · Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 9724387

    Administration of growth factors for the treatment of CNS disorders

    The Regents of the University of California · Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. US 9724339

    Methods and drug products for treating alzheimer's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. US 9717710

    Treatment of mild and moderate Alzheimer's disease

    VTV THERAPEUTICS LLC · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. US 9707220

    Scopolamine for the treatment of depression and anxiety

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. US 9670141

    (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

    Northwestern University · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  26. US 9662322

    Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  27. US 9650352

    Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  28. WO 2017072335

    UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    AB SCIENCE [FR] · Granted Thu May 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  29. US 9616048

    Anti-depression compounds

    The Board of Regents of the University of Texas System · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  30. US 9598414

    Substituted benzo[5,6]azepino[3,2,1-hi]pyrido[4,3-b]indoles and substituted benzo[6,7][1,4]oxazepino[2,3,4-hi]pyrido[4,3-b]indoles for treating CNS disorders

    DAYA DRUG DISCOVERIES, INC. · Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  31. US 9592207

    Intranasal administration of ketamine to treat depression

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  32. US 9585558

    Hyperspectral imaging for early detection of Alzheimer'S Disease

    Regents of the University of Minnesota · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  33. US 9585935

    Intranasal oxytocin treatment to improve schizophrenia

    The Regents of the University of California · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  34. US 9580438

    Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

    4SC DISCOVERY GMBH · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  35. US 9517222

    Method for the treatment of senile dementia of the Alzheimer's type

    Phenomenome Discoveries Inc. · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  36. US 9512212

    Bispecific antibody fragments for neurological disease proteins and methods of use

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  37. US 9512191

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    The Regents of the University of California · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  38. US 9499608

    Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  39. US 9492415

    Methods of treating Parkinson's disease using viral vectors

    The Regents of the University of California · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  40. US 9474787

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  41. US 9468649

    Methods of treating epilepsy with transforming growth factor beta inhibitors

    The Regents of the University of California · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  42. US 9468611

    d-Methadone for the treatment of psychiatric symptoms

    Relmada Therapeutics, Inc. · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  43. US 9446037

    Methods for the treatment of parkinson's disease psychosis using pimavanserin

    ACADIA Pharmaceuticals Inc. · Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  44. US 9376481

    Methods of promoting CNS neuronal repair by inhibiting LRP-1

    The Regents of the University of California · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  45. US 9340576

    Methods of treating depression and other related diseases

    Northwestern University · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  46. US 9333171

    Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

    The Regents of the University of California · Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  47. US 9315534

    Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  48. US 9295674

    Metalloporphyrin neurological treatments

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Neurology & CNS patents are indexed?

289 patents match our Neurology & CNS classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.